Literature DB >> 10644341

Diminished human immunodeficiency virus type 1 reverse transcription and nuclear transport in primary macrophages arrested in early G(1) phase of the cell cycle.

N A Kootstra1, B M Zwart, H Schuitemaker.   

Abstract

Previously, we and others have demonstrated that the process of reverse transcription of human immunodeficiency virus type 1 (HIV-1) is disturbed in nondividing macrophages and quiescent T lymphocytes. Here we analyzed which phase of the cell cycle in macrophages is crucial for early steps in the HIV-1 replication cycle. HIV-1 Ba-L-inoculated macrophages arrested early in the G(1) phase by n-butyrate contained incomplete products of reverse transcription. In gamma-irradiated macrophages, reverse transcription was successfully completed but proviral integration could not be detected. In these cells, nuclear import was disturbed as reflected by the absence of two-long-terminal-repeat circles. In macrophages arrested late in G(1) phase by aphidicolin or 5, 6-dichloro-1-beta-D-ribofuranosyl-benzimidazole (DRB), reverse transcription was unaffected. Proviral integration occurred efficiently in DRB-treated macrophages, whereas integrated proviral DNA could not be detected after aphidicolin treatment. Arrest at G(2) phase of the cell cycle by nocodazole did not affect reverse transcription or proviral integration. Treatment of macrophages with hydroxyurea (HU), which reduces the intracellular deoxynucleoside triphosphate (dNTP) pool by blocking the de novo synthesis of dNTP, resulted in a dose-dependent inhibition of HIV-1 reverse transcription. This could partially be restored by the addition of nucleoside precursors. Addition of nucleoside precursors enhanced both reverse transcription and cell proliferation. However, the disturbed reverse transcription observed in the nonproliferating and n-butyrate-treated macrophages could not be restored by addition of nucleoside precursors. Similar to observations in quiescent T lymphocytes, incomplete proviral DNA species were arrested in the cytoplasm of the macrophages. Our results indicate that also in primary macrophages the intracellular nucleotide pools and other cellular factors that coincide with late G(1) phase of the cell cycle may contribute to efficient reverse transcription and nuclear localization.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10644341      PMCID: PMC111646          DOI: 10.1128/jvi.74.4.1712-1717.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Kinetics of human immunodeficiency virus type 1 reverse transcription in blood mononuclear phagocytes are slowed by limitations of nucleotide precursors.

Authors:  W A O'Brien; A Namazi; H Kalhor; S H Mao; J A Zack; I S Chen
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

2.  Endogenous reverse transcription of human immunodeficiency virus type 1 in physiological microenviroments: an important stage for viral infection of nondividing cells.

Authors:  H Zhang; G Dornadula; R J Pomerantz
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

3.  Reverse transcription takes place within extracellular HIV-1 virions: potential biological significance.

Authors:  H Zhang; Y Zhang; T P Spicer; L Z Abbott; M Abbott; B J Poiesz
Journal:  AIDS Res Hum Retroviruses       Date:  1993-12       Impact factor: 2.205

4.  HIV-1 macrophage tropism is determined at multiple levels of the viral replication cycle.

Authors:  R A Fouchier; M Brouwer; N A Kootstra; H G Huisman; H Schuitemaker
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

5.  Human immunodeficiency virus type 1 replication is blocked prior to reverse transcription and integration in freshly isolated peripheral blood monocytes.

Authors:  S Sonza; A Maerz; N Deacon; J Meanger; J Mills; S Crowe
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

6.  Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2',3'-dideoxynucleoside analogs in resting and activated human cells.

Authors:  W Y Gao; R Agbaria; J S Driscoll; H Mitsuya
Journal:  J Biol Chem       Date:  1994-04-29       Impact factor: 5.157

7.  The nuclear localization signal of the matrix protein of human immunodeficiency virus type 1 allows the establishment of infection in macrophages and quiescent T lymphocytes.

Authors:  U von Schwedler; R S Kornbluth; D Trono
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

8.  The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells.

Authors:  N K Heinzinger; M I Bukrinsky; S A Haggerty; A M Ragland; V Kewalramani; M A Lee; H E Gendelman; L Ratner; M Stevenson; M Emerman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

9.  Role of the karyopherin pathway in human immunodeficiency virus type 1 nuclear import.

Authors:  P Gallay; V Stitt; C Mundy; M Oettinger; D Trono
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

10.  A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells.

Authors:  M I Bukrinsky; S Haggerty; M P Dempsey; N Sharova; A Adzhubel; L Spitz; P Lewis; D Goldfarb; M Emerman; M Stevenson
Journal:  Nature       Date:  1993-10-14       Impact factor: 69.504

View more
  24 in total

1.  Postentry restriction to human immunodeficiency virus-based vector transduction in human monocytes.

Authors:  S Neil; F Martin; Y Ikeda; M Collins
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Transduction efficiency of MLV but not of HIV-1 vectors is pseudotype dependent on human primary T lymphocytes.

Authors:  Michael D Mühlebach; Isabel Schmitt; Stefanie Steidl; Jörn Stitz; Matthias Schweizer; Thomas Blankenstein; Klaus Cichutek; Wolfgang Uckert
Journal:  J Mol Med (Berl)       Date:  2003-10-24       Impact factor: 4.599

3.  Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells.

Authors:  Neeltje A Kootstra; Carsten Munk; Nina Tonnu; Nathaniel R Landau; Inder M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-23       Impact factor: 11.205

4.  Induction of G1 cycle arrest in T lymphocytes results in increased extracellular levels of beta-chemokines: a strategy to inhibit R5 HIV-1.

Authors:  Alonso Heredia; Charles Davis; Anthony Amoroso; Joyelle K Dominique; Nhut Le; Erin Klingebiel; Elise Reardon; Davide Zella; Robert R Redfield
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

5.  Cell cycle requirements for transduction by foamy virus vectors compared to those of oncovirus and lentivirus vectors.

Authors:  Grant Trobridge; David W Russell
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

Review 6.  Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy.

Authors:  Cecilia Frecha; Camille Lévy; François-Loïc Cosset; Els Verhoeyen
Journal:  Mol Ther       Date:  2010-08-24       Impact factor: 11.454

7.  Effect of cell cycle arrest on the activity of nucleoside analogues against human immunodeficiency virus type 1.

Authors:  Sebastien Wurtzer; Séverine Compain; Henri Benech; Allan J Hance; François Clavel
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

8.  Characterization of a late entry event in the replication cycle of human immunodeficiency virus type 2.

Authors:  D J Griffiths; M Dittmar; P Clapham; E Thomas
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

9.  Priming of hepatocytes enhances in vivo liver transduction with lentiviral vectors in adult mice.

Authors:  Virginie Pichard; Sébastien Boni; William Baron; Tuan Huy Nguyen; Nicolas Ferry
Journal:  Hum Gene Ther Methods       Date:  2012-02       Impact factor: 2.396

10.  Host factors that affect Ty3 retrotransposition in Saccharomyces cerevisiae.

Authors:  Michael Aye; Becky Irwin; Nadejda Beliakova-Bethell; Eric Chen; Jennifer Garrus; Suzanne Sandmeyer
Journal:  Genetics       Date:  2004-11       Impact factor: 4.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.